MiMedx Group, Inc. has announced the commercial launch of HELIOGEN™ Fibrillar Collagen Matrix, a new xenograft product designed for complex wound management, especially in surgical settings.

HELIOGEN is a shelf-stable matrix composed of Type I and Type III collagen, replicating the natural composition of structural connective tissue.

They are thrilled to introduce HELIOGEN as our first xenograft product, which complements our existing placental-based solutions in the surgical market.

This launch is a key part of our strategy to expand our surgical product offerings, following the successful introduction of two new products at the end of 2022.

HELIOGEN, named for its triple helical collagen structure, is a significant addition to our portfolio. It provides another option for managing complex wounds.

With strong initial case studies and real-world evidence, we are eager to see how it will benefit our customers and improve patient outcomes.





Source: mimedx.com

Report Abuse